News › GlobeNewswire Inc.

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

GlobeNewswire Inc. • Jan 7, 2026 7:00am (New York) •By Na

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

Syndax Pharmaceuticals and the World Orphan Drug Alliance announced a collaboration to expand access to Revuforj (revumenib), a first-in-class menin inhibitor, through a Managed Access Program in regions including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa where the drug is not yet commercially available.

← Back to news Read Original Article

Insights

RBSFY negative

Jointly fined with parent company Rubis and accused of participating in anti-competitive practices

SNDX positive

The announcement demonstrates strategic expansion of Revuforj's market reach beyond the U.S., enabling access in multiple regions and supporting long-term goals to establish the drug as a standard of care globally. This partnership with WODA enhances the company's mission and market penetration without requiring independent infrastructure development.

Keywords

#managed access program #orphan drug #menin inhibitor #acute leukemia #global expansion #patient access #rare disease

Tickers

SNDX

← Prev: ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram

Next: OSS Announces New Partnership with Leading U.S. Defense Prime to Develop Enhanced Integrated Vision System for U.S. Army →